November 22, 2021

Philips integrates MedChat’s AI capabilities to optimize automated patient communication and hospital workflows

November 22, 2021 Collaboration adds Medchat’s live chat and chatbot services to Philips patient management and informatics platform, Patient Navigation Manager Combined offering allows customers in North America to digitally navigate patients using advanced chatbot services to streamline workflows, quickly resolve patient requests and improve contact center efficiency Amsterdam, the

>

Apollo Funds to Acquire 50% Stake in Broad Reach Power from EnCap

Apollo Funds and existing EnCap-led shareholder group also commit to invest up to $400 million of new equity to accelerate Broad Reach Power’s growth and expansion plans Transaction marks first sale for EnCap Energy Transition Fund I Extends Apollo’s energy transition activity with premier, vertically integrated platform NEW YORK and

>

Sword GRC Wins Rising Star Award From Chartis Research

Global ERM software market-leader Sword GRC secures RiskTech100® 2022 ‘Rising Star’ accolade. Chartis Risk Tech 100 2022 Rising Star Award MAIDENHEAD, England, Nov. 22, 2021 (GLOBE NEWSWIRE) — Sword GRC, a provider of specialist risk, compliance and governance software and services is proud to announce that it has been recognized

>

Philips again a leading company in the Dow Jones Sustainability Indices

November 22, 2021 Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced that it has once again been recognized as one of the leading companies for sustainability performance in the global 2021 Dow Jones Sustainability Indices (DJSI) list. Scoring 81 out

>

Degreed is named a Leader in Learning Management Systems and Experience Platforms

PLEASANTON, Calif., Nov. 22, 2021 (GLOBE NEWSWIRE) — Degreed was among the select companies that Forrester invited to participate in The Forrester Wave™: Learning Management Systems and Experience Platforms, Q4 2021. In this evaluation, Degreed was cited as a Leader and its top scores were in the talent ecosystem integration,

>

Zenas BioPharma Acquires Exclusive Worldwide Rights to Obexelimab from Xencor

Xencor receives rights to additional equity in Zenas as upfront payment and is eligible for up to $480 million in potential milestone payments and royalties on net sales of commercialized products Obexelimab is a novel bifunctional antibody with first-in-class potential to treat autoimmune diseases MONROVIA, Calif., HONG KONG and BOSTON,

>